Traws Pharma ONTX Stock
Traws Pharma Price Chart
Traws Pharma ONTX Financial and Trading Overview
| Traws Pharma stock price | 1 USD |
| Previous Close | 1.16 USD |
| Open | 1.15 USD |
| Bid | 0 USD x 800 |
| Ask | 0 USD x 3000 |
| Day's Range | 1.14 - 1.24 USD |
| 52 Week Range | 0.62 - 1.52 USD |
| Volume | 126.65K USD |
| Avg. Volume | 558.44K USD |
| Market Cap | 25.37M USD |
| Beta (5Y Monthly) | 1.784507 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.5 USD |
ONTX Valuation Measures
| Enterprise Value | -9895312 USD |
| Trailing P/E | N/A |
| Forward P/E | -1.0431035 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 112.27087 |
| Price/Book (mrq) | 1.1090744 |
| Enterprise Value/Revenue | -43.785 |
| Enterprise Value/EBITDA | 0.458 |
Trading Information
Traws Pharma Stock Price History
| Beta (5Y Monthly) | 1.784507 |
| 52-Week Change | 1.68% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 1.52 USD |
| 52 Week Low | 0.62 USD |
| 50-Day Moving Average | 1.08 USD |
| 200-Day Moving Average | 0.91 USD |
ONTX Share Statistics
| Avg. Volume (3 month) | 558.44K USD |
| Avg. Daily Volume (10-Days) | 76.33K USD |
| Shares Outstanding | 20.97M |
| Float | 20.83M |
| Short Ratio | 1.47 |
| % Held by Insiders | 0.46% |
| % Held by Institutions | 7.40% |
| Shares Short | 267.17K |
| Short % of Float | 1.28% |
| Short % of Shares Outstanding | 1.27% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:15 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -9571.68% |
| Gross Margin | 100.00% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -31.26% |
| Return on Equity (ttm) | -63.27% |
Income Statement
| Revenue (ttm) | 226K USD |
| Revenue Per Share (ttm) | 0.01 USD |
| Quarterly Revenue Growth (yoy) | 0% |
| Gross Profit (ttm) | 226K USD |
| EBITDA | -21618000 USD |
| Net Income Avi to Common (ttm) | -20617000 USD |
| Diluted EPS (ttm) | -1.03 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 34.22M USD |
| Total Cash Per Share (mrq) | 1.63 USD |
| Total Debt (mrq) | 0 USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 3.799 |
| Book Value Per Share (mrq) | 1.091 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -16541000 USD |
| Levered Free Cash Flow (ttm) | -9227000 USD |
Profile of Traws Pharma
| Country | United States |
| State | PA |
| City | Newtown |
| Address | 12 Penns Trail |
| ZIP | 18940 |
| Phone | 267 759 3680 |
| Website | https://www.onconova.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 16 |
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. It has a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib in China. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
Q&A For Traws Pharma Stock
What is a current ONTX stock price?
Traws Pharma ONTX stock price today per share is 1 USD.
How to purchase Traws Pharma stock?
You can buy ONTX shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Traws Pharma?
The stock symbol or ticker of Traws Pharma is ONTX.
Which industry does the Traws Pharma company belong to?
The Traws Pharma industry is Biotechnology.
How many shares does Traws Pharma have in circulation?
The max supply of Traws Pharma shares is 21M.
What is Traws Pharma Price to Earnings Ratio (PE Ratio)?
Traws Pharma PE Ratio is 0.00000000 now.
What was Traws Pharma earnings per share over the trailing 12 months (TTM)?
Traws Pharma EPS is 0 USD over the trailing 12 months.
Which sector does the Traws Pharma company belong to?
The Traws Pharma sector is Healthcare.
Traws Pharma ONTX included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 19199.16 USD — |
+2.47
|
8.02B USD — | 18961.69 USD — | 19210.95 USD — | — - | 8.02B USD — |
| NASDAQ Composite Total Return XCMP | 23521.22 USD — |
+2.47
|
— — | 23230.28 USD — | 23535.65 USD — | — - | — — |
| NASDAQ Capital Market Composite RCMP | 114.46 USD — |
+1.8
|
— — | 113.76 USD — | 115.05 USD — | — - | — — |
| Nasdaq Health Care IXHC | 946.2 USD — |
+1.52
|
— — | 941.18 USD — | 951.02 USD — | — - | — — |
- {{ link.label }} {{link}}